Information on the prognostic significance of chromosome 17 abnormalities in MDS seems to be highly valuable in the era of hypomethylating agents, especially since patients with MDS and AML with TP53 mutations or a poor cytogenetic profile have been recently shown to have a favorable response to decitabine.4 Here, TP53 is linked to myelodysplastic syndrome.